Irfan Hassam-Malani

Associate

  • Irfan Hassam-Malani
  • Phone: +1 312 499 6708

    Irfan Hassam-Malani - LinkedIn Import to Address Book

  • Duane Morris LLP
    190 South LaSalle Street, Suite 3700
    Chicago, IL 60603-3433
    USA

Irfan Hassam-Malani practices in the area of intellectual property law. Mr. Hassam-Malani has experience with counseling clients through patent preparation and prosecution, product clearance and litigation, working primarily with large global manufacturers in the consumer electronics, telecommunications, chemical and agricultural sciences industries. He has also managed extensive global patent portfolio and application strategy for a worldwide leader in aviation technology.

Mr. Hassam-Malani is a 2021 cum laude graduate of the University of Illinois at Urbana-Champaign College of Law, where he was notes editor of the Elder Law Journal, and a graduate of the University of Illinois at Urbana-Champaign (B.S., Chemistry; B.A.&Sc., Economics). He speaks English and Hindi.

Admissions

  • Illinois
  • U.S. Patent and Trademark Office (USPTO)

Education

  • University of Illinois College of Law, J.D., cum laude, 2021
    - Notes Editor, The Elder Law Journal
  • University of Illinois at Urbana-Champaign, B.S., Chemistry, 2018
  • University of Illinois at Urbana-Champaign, B.A.&Sc., Economics, 2018

Experience

  • Duane Morris LLP
    - Associate, 2022-present
  • Fitch, Even, Tabin & Flannery LLP
    - Associate, 2021-2022

Professional Activities

  • Chicago Bar Association
    - Member, 2021-present
  • South Asian Bar Association
    - Member, 2021-present

Honors and Awards

  • Recipient of CALI Award in Patent Research & Strategy
  • ABA Client Counseling Competition Semi-Finalist
  • Advanced Trial Team Quarterfinalist and Finalist
  • Williams Institute Moot Court Competition Team

Selected Publications

Representative Matters

  • Represented Somerset Therapeutics LLC in settling Hatch-Waxman litigation related to 0.7% olopatadine ophthalmic solution in the United States, a generic version of PATADAY® Once-Daily, permitting entry into the market prior to patent expiry.